Paper41314865
Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad.
Sinkey RG and 6 others. J Cyst Fibros, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. Papers, record 41314865. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41314865
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad.
- PubMed
- Publication types
- Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cystic Fibrosis | Major topic |
| Aminophenols | Major topic |
| Fetal Blood | Major topic |
| Milk, Human | Major topic |
| Quinolones | Major topic |
| Benzodioxoles | Major topic |
| Indoles | Major topic |
| Pyrazoles | Major topic |
| Phenylpropionates | Major topic |
| Pyridines | Major topic |
| Pyrrolidines | Major topic |
| Humans | |
| Female | |
| Pregnancy | |
| Infant, Newborn | |
| Drug Combinations | |
| Adult | |
| Chloride Channel Agonists | |
| Cystic Fibrosis Transmembrane Conductance Regulator | |
| Quinolines |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K23 HL159331 | NHLBI NIH HHS | United States | K23HL159331 | PubMed | NIH RePORTER |
| R01 HD117940 | NICHD NIH HHS | United States | R01HD117940 | PubMed | NIH RePORTER |
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35440408 | Current prices versus minimum costs of production for CFTR modulators. | J Cyst Fibros | 2022 | https://conductscience.org/library/papers/35440408 | PubMed |
| 2 | 41037817 | Pregnancy in Patients With Cystic Fibrosis. | Obstet Gynecol | 2026 | https://conductscience.org/library/papers/41037817 | PubMed |
| 3 | 38876833 | Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies. | J Cyst Fibros | 2024 | https://conductscience.org/library/papers/38876833 | PubMed |
| 4 | 39666984 | Pregnancy in People With Cystic Fibrosis Treated With Highly Effective Modulator Therapy. | Obstet Gynecol | 2025 | https://conductscience.org/library/papers/39666984 | PubMed |
| 5 | 40399734 | Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review. | Clin Pharmacokinet | 2025 | https://conductscience.org/library/papers/40399734 | PubMed |
| 6 | 40121139 | Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant. | J Cyst Fibros | 2025 | https://conductscience.org/library/papers/40121139 | PubMed |
| 7 | 25455573 | Maternal medication, drug use, and breastfeeding. | Child Adolesc Psychiatr Clin N Am | 2015 | https://conductscience.org/library/papers/25455573 | PubMed |
| 8 | 36371965 | Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate. | J Chromatogr B Analyt Technol Biomed Life Sci | 2022 | https://conductscience.org/library/papers/36371965 | PubMed |
| 9 | 40133101 | First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study. | J Cyst Fibros | 2025 | https://conductscience.org/library/papers/40133101 | PubMed |
| 10 | 38964603 | Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia. | Pulm Pharmacol Ther | 2024 | https://conductscience.org/library/papers/38964603 | PubMed |
| 11 | 38232663 | Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model. | Biomed Pharmacother | 2024 | https://conductscience.org/library/papers/38232663 | PubMed |
| 12 | 33846105 | Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. | J Cyst Fibros | 2021 | https://conductscience.org/library/papers/33846105 | PubMed |
| 13 | 36996799 | Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis. | Fetal Diagn Ther | 2023 | https://conductscience.org/library/papers/36996799 | PubMed |
| 14 | 39645477 | Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. | J Cyst Fibros | 2025 | https://conductscience.org/library/papers/39645477 | PubMed |
| 15 | 35422395 | A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. | J Cyst Fibros | 2022 | https://conductscience.org/library/papers/35422395 | PubMed |
| 16 | 37690692 | Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics. | J Biol Chem | 2023 | https://conductscience.org/library/papers/37690692 | PubMed |
| 17 | 40118755 | CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful case. | J Cyst Fibros | 2025 | https://conductscience.org/library/papers/40118755 | PubMed |
| 18 | 34952795 | Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. | J Cyst Fibros | 2022 | https://conductscience.org/library/papers/34952795 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42819752 | Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions. | Pregnancy (Hoboken) | 2026 | https://conductscience.org/library/papers/42819752 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41314865
GET https://conductscience.org/api/papers/v1/41314865/authors